Concepedia

Publication | Open Access

The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab

DOIFull Paper Access

66

Citations

18

References

2015

Year

Sella Aarrestad Provan, Inger Jorid Berg, Hilde Berner Hammer, Alexander Mathiessen, Tore K Kvien, Anne Grete Semb
PLoS ONE

Abstract

Treatment with tocilizumab and rituximab reduces PWV, a marker of CVD risk, in patients with RA.

References

YearCitations

Page 1